124 related articles for article (PubMed ID: 36539001)
21. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
22. lncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis.
Zhu L; Wang F; Fan W; Jin Z; Teng C; Zhang J
Acta Biochim Biophys Sin (Shanghai); 2021 Aug; 53(9):1198-1206. PubMed ID: 34327529
[TBL] [Abstract][Full Text] [Related]
23. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
Zang H; Li Y; Zhang X; Huang G
Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
[TBL] [Abstract][Full Text] [Related]
24. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
Gao W; Guo H; Niu M; Zheng X; Zhang Y; Xue X; Bo Y; Guan X; Li Z; Guo Y; He L; Zhang Y; Li L; Cao J; Wu Y
Mol Cancer; 2020 Nov; 19(1):166. PubMed ID: 33234130
[TBL] [Abstract][Full Text] [Related]
25. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
Tao L; Wu YQ; Zhang SP
Neoplasma; 2019 Sep; 66(5):746-755. PubMed ID: 31169019
[TBL] [Abstract][Full Text] [Related]
26. miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.
Jin J; Sun Z; Yang F; Tang L; Chen W; Guan X
Arch Biochem Biophys; 2018 May; 645():54-60. PubMed ID: 29550144
[TBL] [Abstract][Full Text] [Related]
27. Homoharringtonine inhibited breast cancer cells growth via miR-18a-3p/AKT/mTOR signaling pathway.
Wang LB; Wang DN; Wu LG; Cao J; Tian JH; Liu R; Ma R; Yu JJ; Wang J; Huang Q; Xiong WY; Zhang X
Int J Biol Sci; 2021; 17(4):995-1009. PubMed ID: 33867824
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting autophagy by miR-19a-3p/PTEN regulation protected retinal pigment epithelial cells from hyperglycemic damage.
Gong Q; Luo D; Wang H; Xu X; Fan Y; Zheng Z; Qian T
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119530. PubMed ID: 37393018
[TBL] [Abstract][Full Text] [Related]
29. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
30. miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells.
Chen D; Si W; Shen J; Du C; Lou W; Bao C; Zheng H; Pan J; Zhong G; Xu L; Fu P; Fan W
Cell Death Dis; 2018 Feb; 9(2):188. PubMed ID: 29416005
[TBL] [Abstract][Full Text] [Related]
31. MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1.
Bao C; Chen J; Chen D; Lu Y; Lou W; Ding B; Xu L; Fan W
Cell Death Dis; 2020 Aug; 11(8):618. PubMed ID: 32796817
[TBL] [Abstract][Full Text] [Related]
32. MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.
Zhang LY; Yu JY; Leng YL; Zhu RR; Liu HX; Wang XY; Yang TT; Guo YN; Tang JL; Zhang XC
Cancer Gene Ther; 2022 Jun; 29(6):770-783. PubMed ID: 34145425
[TBL] [Abstract][Full Text] [Related]
33. MiR-18a upregulation enhances autophagy in triple negative cancer cells via inhibiting mTOR signaling pathway.
Fan YX; Dai YZ; Wang XL; Ren YQ; Han JJ; Zhang H
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2194-200. PubMed ID: 27338042
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
36. MiR-454-3p promotes apoptosis and autophagy of AML cells by targeting ZEB2 and regulating AKT/mTOR pathway.
Wang X; Zhong L; Dan W; Chu X; Luo X; Liu C; Wan P; Lu Y; Liu Z; Zhang Z; Liu B
Hematology; 2023 Dec; 28(1):2223874. PubMed ID: 37313984
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-520a-3p inhibits cell growth and metastasis of non-small cell lung cancer through PI3K/AKT/mTOR signaling pathway.
Lv X; Li CY; Han P; Xu XY
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(8):2321-2327. PubMed ID: 29762835
[TBL] [Abstract][Full Text] [Related]
38. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Hu Z; Cai M; Zhang Y; Tao L; Guo R
Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
[TBL] [Abstract][Full Text] [Related]
39. miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines.
Guan X; Guan Y
Neoplasma; 2020 Sep; 67(5):972-981. PubMed ID: 32412771
[TBL] [Abstract][Full Text] [Related]
40. miR-410-3p promotes prostate cancer progression via regulating PTEN/AKT/mTOR signaling pathway.
Zhang Y; Zhang D; Lv J; Wang S; Zhang Q
Biochem Biophys Res Commun; 2018 Sep; 503(4):2459-2465. PubMed ID: 29969630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
